Caplacizumab-yhdp - Biologic Drug Details

Summary for caplacizumab-yhdp

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for caplacizumab-yhdp Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for caplacizumab-yhdp Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for caplacizumab-yhdp Derived from Patent Text Search

No patents found based on company disclosures

Caplacizumab-yhdp: Market Dynamics and Financial Trajectory

Last updated: February 27, 2026

What is Caplacizumab-yhdp and How Does It Function?

Caplacizumab-yhdp is a biologic drug approved for acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood disorder. It is a nanobody targeting von Willebrand factor (vWF), preventing platelet aggregation and microvascular thrombosis. The drug's trade name is Cablivi (by Genentech/Roche), approved by the FDA in February 2019 and European Medicines Agency (EMA) in July 2019.[1][2]

What Are Currently the Market Size and Key Drivers?

Market Size

• Estimated global aTTP treatment market valued at approximately $500 million in 2022.
• Anticipated Compound Annual Growth Rate (CAGR) of around 25% from 2022 to 2030.
• North America accounts for 60% of revenue; Europe provides 30%; the remainder is from Asia Pacific.

Key Market Drivers

1. Approval and Adoption: Approval by major regulators facilitated clinical adoption.
2. Orphan Disease Status: aTTP qualifies for orphan drug incentives, reducing development costs.
3. Limited Alternatives: Prior to caplacizumab, treatment options were plasma exchange and immunosuppressants with variable outcomes.
4. Increasing Diagnosis Rates: Improved awareness elevates diagnosis, expanding the eligible patient pool.
5. Pricing Strategies: Price per dose ranges from $22,000 to $30,000, reflecting high-value biologic pricing models.

Competitive Landscape

• No direct competitors for targeted nanobody approach.
• Rituximab used off-label in some cases.
• Need to watch for biosimilar or biosimilar-like entrants in similar space.

What Are the Financial Trajectory and Revenue Projections?

Revenue Generation and Growth

Year	Revenue (USD million)	Growth Rate
2022	50	-
2023	100	100%
2024	150	50%
2025	225	50%
2026	338	50%

Assuming the current rate of market expansion and increasing adoption, revenues could reach $338 million by 2026, nearly tripling from the 2022 baseline.

Cost Considerations

• Development costs are largely sunk; manufacturing costs are estimated at $8,000 to $10,000 per treatment course.[3]
• Marketing and distribution costs remain significant due to the high-price point and specialist channels.

Profitability Outlook

• Pricing strategies and market penetration forecast gross margins of 60-70%.
• Net margins depend heavily on volume scaling and managed care negotiations.
• Break-even expected within 2-3 years post-launch expansion.

What Are Potential Market Expansion Opportunities?

1. Indication Expansion: Research into caplacizumab for other thrombotic disorders.
2. Geographic Expansion: Entry into emerging markets, where orphan designation and pricing could differ.
3. Combination Therapies: Use alongside immunosuppressants or plasma exchange protocols.
4. Market Penetration: Heightened awareness and clinician education increase adoption rates.

What Are Challenges Affecting Market and Financial Success?

• Pricing and Reimbursement: Payer resistance in some markets could limit access.
• Small Patient Population: Diagnosis rate varies; logistical challenges exist in low-resource settings.
• Competitive Developments: Emerging therapies targeting vWF or alternative pathways could erode market share.
• Regulatory Risks: Changes in orphan drug policy or approval standards could impact timelines and costs.

What Is the Timeline for Market Growth and Product Adoption?

• 2023-2024: Increased adoption driven by clinical guidelines and expanded clinician awareness.
• 2025: Entry into additional European markets with reimbursement processes settling.
• 2026 and beyond: Broader adoption, possible indication expansion, and evolution of competition.

Key Takeaways

• Caplacizumab-yhdp benefits from orphan status, rapid market growth, and lack of direct competition.
• Revenue is projected to grow substantially from 2022 to 2026, with potential adjustments based on pricing negotiations and regulatory changes.
• Market size remains limited due to disease rarity but offers high-value, high-margin opportunities.
• Challenges include reimbursement hurdles, diagnostic variability, and emerging competitors.

FAQs

1. What factors influence caplacizumab-yhdp's market penetration?
Clinician awareness, regulatory approvals, reimbursement policies, and clinical guidelines shape adoption.

2. How does pricing impact revenue growth?
High per-dose pricing supports revenue but may limit access depending on payer negotiations, influencing overall market share.

3. Are there other drugs similar to caplacizumab-yhdp?
No direct nanobody competitors; standard treatment includes plasma exchange and immunosuppressants, with no targeted biologic options.

4. What are the prospects for indication expansion?
Potential exists for off-label use in other thrombotic microangiopathies or research into broader coagulopathies.

5. How does regional regulation affect market expansion?
Regulatory approval timelines, pricing policies, and healthcare infrastructure in emerging markets influence global reach.

References

[1] Food and Drug Administration. (2019). Cablivi (caplacizumab-yhdp) approval.
[2] European Medicines Agency. (2019). Cablivi approval.
[3] BioPharma Dive. (2022). Pricing insights for orphan biologics.